

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
ADDRESS: 102 CHI LANG STREET, NGUYEN TRAI WARD, HAI DUONG CITY, HAI DUONG, VIETNAM  
TAXCODE: 0800011018

# **FINANCIAL REPORT**

## **QUARTER I, 2025**

*ESTABLISHED AT : MARCH 31,2025*

**including :**

- 1- CONSOLIDATED BANLANCE SHEET
- 2- QUARTERLY CONSOLIDATED INCOME STATEMENT
- 3- STATEMENT OF CASH FLOWS
- 4- NOTES TO FINANCIAL STATEMENT

Place of receipt :.....



## CONSOLIDATED BALANCE SHEET

Prepared as of: 31 / 3 / 2025

Unit: VND

Items	Code	Notes	Closing Balance	Opening Balance
1	2	3	4	5
<b>ASSET</b>				
<b>A – SHORT-TERM ASSETS</b>	<b>100</b>		<b>386.808.898.646</b>	<b>341.148.607.589</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>		<b>40.052.093.062</b>	<b>31.419.168.182</b>
1. Cash	111		40.052.093.062	31.419.168.182
2. Cash equivalents	112			
<b>II. Short-term investments</b>	<b>120</b>			
1. Trading securities	121			
2. Allowances for decline in value of trading	122			
3. Held to maturity investments	123			
<b>III. Short-term receivables</b>	<b>130</b>		<b>208.521.777.210</b>	<b>180.755.628.545</b>
1. Short-term trade receivables	131		116.040.539.431	118.236.171.594
2. Short-term repayments to suppliers	132		89.564.678.572	59.671.572.390
3. Short-term intra-company receivables	133			
4. Receivables under schedule of construction	134			
5. Short-term loan receivables	135			
6. Other short-term receivables	136		6.587.944.270	6.519.269.624
7. Short-term allowances for doubtful debts (*)	137		(3.671.385.063)	(3.671.385.063)
8. Shortage of assets awaiting resolution	139			
<b>IV. Inventories</b>	<b>140</b>		<b>136.027.980.834</b>	<b>127.909.053.084</b>
1. Inventories	141		136.027.980.834	127.909.053.084
2. Allowances for decline in value of inventories	149			
<b>V. Other current assets</b>	<b>150</b>		<b>2.207.047.540</b>	<b>1.064.757.778</b>
1. Short-term prepaid expenses	151		522.496.858	624.164.224
2. Deductible VAT	152		1.281.484.091	440.593.554
3. Taxes and other receivables from government	153		403.066.591	
4. Government bonds purchased for resale	154			
5. Other current assets	155			
<b>B – LONG-TERM ASSETS</b>	<b>200</b>		<b>310.659.506.830</b>	<b>305.237.748.766</b>
<b>I. Long-term receivables</b>	<b>210</b>			
1. Long-term trade receivables	211			
2. Long-term repayments to suppliers	212			
3. Working capital provided to sub-units	213			
4. Long-term intra-company receivables	214			
5. Long-term loan receivables	215			
6. Other long-term receivables	216			
7. Long-term allowances for doubtful debts (*)	219			
<b>II. Fixed assets</b>	<b>220</b>		<b>272.500.458.274</b>	<b>277.938.572.145</b>
<b>1. Tangible fixed assets</b>	<b>221</b>		<b>254.249.107.918</b>	<b>259.687.221.789</b>
- Historical costs	222		478.797.718.556	481.416.768.768
- Accumulated depreciation (*)	223		(224.548.610.638)	(221.729.546.979)
<b>2. Finance lease fixed assets</b>	<b>224</b>			
- Historical costs	225			
- Accumulated depreciation (*)	226			
<b>3. Intangible fixed assets</b>	<b>227</b>		<b>18.251.350.356</b>	<b>18.251.350.356</b>



- Historical costs	228		25.557.287.846	25.557.287.846
- Accumulated depreciation (*)	229		(7.305.937.490)	(7.305.937.490)
<b>III. Investment properties</b>	<b>230</b>			
- Historical costs	231			
- Accumulated depreciation (*)	232			
<b>IV. Long-term assets in progress</b>	<b>240</b>		<b>35.808.425.769</b>	<b>24.432.507.459</b>
1. Long-term work in progress	241			
2. Construction in progress	242		35.808.425.769	24.432.507.459
<b>V. Long-term investments</b>	<b>250</b>			
1. Investments in subsidiaries	251			
2. Investments in joint ventures and associates	252			
3. Investments in equity of other entities	253			
4. Allowances for long-term investments (*)	254			
5. Held to maturity investments	255			
<b>VI. Other long-term assets</b>	<b>260</b>		<b>2.350.622.787</b>	<b>2.866.669.162</b>
1. Long-term prepaid expenses	261		2.350.622.787	2.866.669.162
2. Deferred income tax assets	262			
3. Long-term equipment and spare parts for	263			
4. Other long-term assets	268			
<b>TOTAL ASSETS</b>	<b>270</b>		<b>697.468.405.476</b>	<b>646.386.356.355</b>
<b>RESOURCES</b>				
<b>C - LIABILITIES</b>	<b>300</b>		<b>229.904.494.329</b>	<b>192.127.190.710</b>
<b>I. Short-term liabilities</b>	<b>310</b>		<b>186.527.742.982</b>	<b>186.108.895.749</b>
1. Short-term trade payables	311		59.287.562.007	63.913.046.095
2. Short-term prepayments from customers	312		22.740.801.062	27.011.433.156
3. Taxes and other payables to government	313		3.826.186.376	7.152.037.955
4. Payables to employees	314		18.121.740.295	4.869.401.998
5. Short-term accrued expenses	315		1.115.501.966	428.162.066
6. Short-term intra-company payables	316			
7. Payables under schedule of construction	317			
8. Short-term unearned revenues	318		1.925.701.537	3.201.934.270
9. Other short-term payments	319		8.958.507.742	7.182.181.347
10. Short-term borrowings and finance lease	320		63.336.807.542	65.925.328.072
11. Short-term provisions (*)	321		867.363.665	
12. Bonus and welfare fund	322		6.347.570.790	6.425.370.790
13. Price stabilization fund	323			
14. Government bonds purchased for resale	324			
<b>II. Long-term liabilities</b>	<b>330</b>		<b>43.376.751.347</b>	<b>6.018.294.961</b>
1. Long-term trade payables	331			
2. Long-term repayments from customers	332			
3. Long-term accrued expenses	333			
4. Intra-company payables for operating capital	334			
5. Long-term intra-company payables	335			
6. Long-term unearned revenues	336			
7. Other long-term payables	337			
8. Long-term borrowings and finance lease	338		43.363.569.440	6.002.713.990
9. Convertible bonds	339			
10. Preference shares	340			
11. Deferred income tax payables	341			
12. Long-term provisions	342			
13. Science and technology development fund	343		13.181.907	15.580.971
<b>D - OWNER'S EQUITY</b>	<b>400</b>		<b>467.563.911.147</b>	<b>454.259.165.645</b>
<b>I. Owner's equity</b>	<b>410</b>		<b>467.563.911.147</b>	<b>454.259.165.645</b>
1. Contributed capital	411		279.473.170.000	279.473.170.000
- Ordinary shares with voting rights	411		279.473.170.000	279.473.170.000

- Preference shares	411			
2. Capital surplus	412			
3. Conversion options on convertible bonds	413			
4. Other capital	414			
5. Treasury shares (*)	415			
6. Differences upon asset revaluation	416			
7. Exchange rate differences	417			
8. Development and investment funds	418		124.594.214.888	124.594.214.888
9. Enterprise reorganization assistance fund	419			
10. Other equity funds	420			
11. Undistributed profit after tax	421		63.496.526.259	50.191.780.757
- Undistributed profit after tax brought	421		50.191.780.757	9.870.172.861
- Undistributed profit after tax for the current	421		13.304.745.502	40.321.607.896
12. Capital expenditure funds	422			
<b>II. Funding sources and other funds</b>	<b>430</b>			
1. Funding sources	431			
2. Funds used for fixed asset acquisition	432			
<b>TOTAL SOURCES</b>	<b>440</b>		<b>697.468.405.476</b>	<b>646.386.356.355</b>

Prepared by  
(Signature and full name)

*Trần Quốc Tuấn*

Chief accountant  
(Signature and full name)

**KẾ TOÁN TRƯỞNG**  
**CNKT: CHU VĂN LONG**

April 18 2025  
Director  
(Signature, full name and stamp)

**TỔNG GIÁM ĐỐC**  
**ĐSK1: NGUYỄN THỊ TÚ ANH**



## QUARTERLY CONSOLIDATED INCOME STATEMENT

### QUARTER I/2025

Unit: VND

Item	Code	Description	Quarter I		Accumulation from the beginning of the fiscal year to at the end of current quarter	
			Current year	Previous period	Current year	Previous year
1	2	3	4	5	6	7
1. Revenues from sales and services rendered	01	25	161.570.158.355	146.660.709.799	161.570.158.355	146.660.709.799
2. Revenue deductions	02		676.922.196	110.115.466	676.922.196	110.115.466
3. Net revenues from sales and services rendered	03		160.893.236.159	146.550.594.333	160.893.236.159	146.550.594.333
4. Costs of goods sold	04	27	100.907.297.970	100.098.766.991	100.907.297.970	100.098.766.991
5. Gross revenues from sales and services rendered	05		59.985.938.189	46.451.827.342	59.985.938.189	46.451.827.342
6. Financial income	06	26	164.862.480	67.873.651	164.862.480	67.873.651
7. Financial expenses	07	28	1.439.046.991	1.932.841.649	1.439.046.991	1.932.841.649
- In which: Interest expenses	23		729.036.031	1.038.232.196	729.036.031	1.038.232.196
8. Selling expenses	25		20.770.275.738	17.781.438.760	20.770.275.738	17.781.438.760
9. General administration expenses	26		21.439.060.473	16.910.555.552	21.439.060.473	16.910.555.552
10. Net profits from operating activities	30		16.502.417.467	9.894.865.032	16.502.417.467	9.894.865.032
11. Other income	31		129.578.238	260.535.184	129.578.238	260.535.184
12. Other expenses	32		1.063.827	8.644.820	1.063.827	8.644.820
13. Other profits	40		128.514.411	251.890.364	128.514.411	251.890.364
14. Total net profit before tax	50		16.630.931.878	10.146.755.396	16.630.931.878	10.146.755.396
15. Current corporate income tax	51	30	3.326.186.376	2.029.351.079	3.326.186.376	2.029.351.079
16. Deferred corporate income tax	52	30				
17. Profits after enterprise income	60		13.304.745.502	8.117.404.317	13.304.745.502	8.117.404.317
18. Basic earnings per share	70		476	398	476	398
19. Diluted earnings per share	71		476	398	476	398
20. Value per share	72		10.000	10.000	10.000	10.000

April 18, 2025

**Prepared by**  
(Signature and full name)

  
**Trần Quốc Tuấn**

**Chief Accountant**  
(Signature and full name)

  
**KẾ TOÁN TRƯỞNG**  
**CNKT: CHU VĂN LONG**

**Director**

(Signature, full name and stamp)



**TỔNG GIÁM ĐỐC**  
**ĐSK: NGUYỄN THỊ TÚ ANH**



# INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Indirect method)  
Quarter I/2025


Unit: VND


Item	Code	Description	Accumulation from the beginning of the fiscal year to at the end of current quarter	
			This year	Previous year
1	2	3	4	5
<b>I. Cash flows from operating activities</b>				
1. Profit before tax	01		16.630.931.878	10.146.755.396
2. Adjustments for			7.740.811.388	7.822.216.701
- Depreciation of fixed assets and investment properties	02		6.164.395.807	6.777.068.686
- Provisions	03		867.363.665	
- Gains (losses) on exchange rate differences from revaluation of accounts derived from foreign currencies	04			
- Gains (losses) on investing activities	05		(19.984.115)	6.915.819
- Interest expenses	06		729.036.031	1.038.232.196
- Other adjustments	07			
3. Operating profit before changes in working capital	08		24.371.743.266	17.968.972.097
- Increase (decrease) in receivables	09		(28.607.039.202)	(26.190.183.643)
- Increase (decrease) in inventories	10		(8.118.927.750)	(5.578.445.748)
- Increase (decrease) in payables (exclusive of interest payables, enterprise income tax payables)	11		2.267.865.808	37.115.870.961
- Increase (decrease) in prepaid expenses	12		617.713.741	1.726.639.078
- Increase (decrease) in trading securities	13			
- Interest paid	14		(729.036.031)	(1.038.232.196)
- Enterprise income tax paid	15		(6.302.229.077)	(1.833.691.588)
- Other receipts from operating activities	16			0
- Other payments on operating activities	17		(77.800.000)	(114.000.000)
Net cash flows from operating activities	20		(16.577.709.245)	22.056.928.961
<b>II. Cash flows from investing activities</b>				
1. Purchase or construction of fixed assets and other long-term assets	21	6,7,8,11	(9.581.684.910)	(1.409.669.692)
2. Proceeds from disposals of fixed assets and other long-term assets	22		12.785.455	
3. Loans and purchase of debt instruments from other entities	23			
4. Collection of loans and repurchase of debt instruments of other	24			
5. Equity investments in other entities	25			
6. Proceeds from equity investment in other entities	26			
7. Interest and dividend received	27		7.198.660	(6.915.819)
Net cash flows from investing activities	30		(9.561.700.795)	(1.416.585.511)
<b>III. Cash flows from financial activities</b>				
1. Proceeds from issuance of shares and receipt of contributed capital	31	21		
2. Repayments of contributed capital and repurchase of stock issued	32	21		
3. Proceeds from borrowings	33		69.133.866.843	34.174.472.901
4. Repayment of principal	34		(34.361.531.923)	(43.123.973.200)
5. Repayment of financial principal	35			
6. Dividends or profits paid to owners	36	21		
Net cash flows from financial activities	40		34.772.334.920	(8.949.500.299)
Net cash flows during the fiscal year (20+30+40)	50		8.632.924.880	11.690.843.151
Cash and cash equivalents at the beginning of fiscal year	60		31.419.168.182	25.418.100.057
Effect of exchange rate fluctuations	61		0	0
Cash and cash equivalents at the end of fiscal year (50+60+61)	70	29	40.052.093.062	37.108.943.208

Prepared by  
(Signature and full name)

  
Trần Quốc Tuấn

Chief Accountant  
(Signature and full name)

  
KẾ TOÁN TRƯỞNG  
CNKT: CHU VĂN LONG

Director  
(Signature, full name and stamp)  
  
SỞNG GIÁM ĐỐC  
ĐẠCK I: NGUYỄN THỊ TÚ ANH



## NOTES TO FINANCIAL STATEMENT

### Quarter : I/2025

#### I. ENTERPRISE INFORMATION

##### 1. Form of ownership:

Hai Duong Pharmaceutical Medical Materials Joint Stock Company (the Company) was converted from Hai Duong Pharmaceutical and Medical Supplies Company according to Decision No. 5943/QD/UB dated December 17, 2002, by the Hai Duong Provincial People's Committee on the transformation of a state-owned enterprise into a joint-stock company. The Company operates under Business Registration Certificate No. 0403000046 issued by the Hai Duong Department of Planning and Investment on April 4, 2003; amended for the 21st time on June 07, 2024, with the Enterprise Code: 0800011018.

##### 2. Fields

Manufacturing of pharmaceuticals, chemicals, and medicinal materials; manufacturing of medical, dental, orthopedic, and rehabilitation equipment; manufacturing of functional foods not elsewhere classified; manufacturing of cosmetics; wholesale of pharmaceuticals and medical equipment; wholesale of other foods; wholesale of perfumes, cosmetics, and hygiene products; wholesale of other chemicals; wholesale of medical machinery and equipment; other specialized wholesale not elsewhere classified; retail of pharmaceuticals, medical equipment, cosmetics, and hygiene products in specialized stores; retail of other chemicals not elsewhere classified in specialized stores; retail of other functional foods in specialized stores; retail of watches and eyewear in specialized stores; cultivation of medicinal plants; printing; other professional scientific activities not elsewhere classified; road freight transport; agency services; real estate business, land use rights owned, used, or leased; hotels; other personal service activities not elsewhere classified; distillation, rectification, and blending of spirits; production of wine; production of beer and malt beverages; production of non-alcoholic beverages, mineral water; construction of all types of buildings; construction of utility projects; construction of other civil engineering projects; demolition; site preparation; installation of electrical systems; installation of water supply, sewerage, heating, and air-conditioning systems; installation of other construction systems; completion of construction projects; other specialized construction activities; wholesale of beverages; retail of beverages in specialized stores; advertising; market research and public opinion polling; preschool education; organization of conventions and trade shows

Authorized capital: 279.473.170.000 VND

(By words: Hai trăm bảy mươi chín tỷ bốn trăm bảy mươi ba triệu một trăm bảy mươi nghìn đồng)

List of shareholders at 30/06/2025

Item	Type of shares	Number of shares	Value of shares	Contribution rate
- Individual shareholders	Ordinary shares	27.947.317	279.473.170.000	100%
Total		27.947.317	279.473.170.000	

Headquarters: Số 102 Phố Chi Lăng, P. Nguyễn Trãi, TP Hải Dương, Tỉnh Hải Dương  
Taxcode: 0800011018

#### II. ACCOUNTING PERIOD AND ACCOUNTING CURRENCY

1. Fiscal year (from 01/01 to 31/12).
2. Accounting currency: Viet Nam Dong

#### III. ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM

1. Accounting system: Circular No. 200/2014/TT-BTC dated December 22, 2014 of the Ministry of Finance.
2. Accounting form: Vouchers for book entry

**IV. DECLARATION OF ADHERENCE TO ACCOUNTING STANDARDS AND ACCOUNTING SYSTEM**  
We, Hai Duong Pharmaceutical Medical Materials Joint Stock Company, declare that we comply with the Vietnamese Accounting Standards and Vietnamese Accounting System.

#### V. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

##### 1. Rules for recording cash and cash equivalents.

Cash, bank deposits, and cash in transit include:

Principles for determining cash equivalents:

These are short-term investments with a maturity of no more than three months that can be easily converted into cash with minimal risk of value changes from the purchase date at the reporting date.

Principles and methods for converting foreign currencies into the accounting currency:

Transactions denominated in foreign currencies are converted into Vietnamese Dong using the average interbank exchange rate announced by the bank where the company maintains its account at the transaction date. At year-end, monetary items in foreign currencies are revalued based on the average interbank exchange rate published by the same bank as of the end of the fiscal year.

Exchange rate differences arising during the period and those resulting from the revaluation of monetary item balances at year-end.

Are transferred to financial income or expenses in the financial year.

#### **4. Rules for recording depreciation of fixed assets**

Recognition of Tangible and Intangible Fixed Assets:

The company's fixed assets are recorded at their cost, accumulated depreciation, and carrying value. The cost of fixed assets includes the purchase price, import taxes, transportation costs, installation, testing, and other related costs necessary to bring the asset into a condition for use.

Depreciation Method for Tangible and Intangible Fixed Assets:

Depreciation is calculated using the straight-line method, based on the estimated useful life of the asset. The depreciation rate applied is in accordance with the rates stipulated in Circular No. 45/2013/TT-BTC dated April 25, 2013, issued by the Ministry of Finance.

#### **5. Accounting rules for payables**

Accounts Payable, Intercompany Payables, Other Payables, and Loans at the Reporting Date:

- . Payables with a payment term of less than 1 year or within one operating cycle are classified as current liabilities.
- . Payables with a payment term of more than 1 year or beyond one operating cycle are classified as non-current liabilities.
- . Assets pending resolution are classified as current liabilities.
- . Deferred tax liabilities are classified as non-current liabilities.

#### **6. Accounting rules for prepaid expenses.**



Prepaid expenses related to the current fiscal year's production and business expenses are recognized as short-term prepaid expenses.

The following expenses incurred during the fiscal year but accounted for as long-term prepaid expenses to be gradually amortized into the operating results:

- . High-value tools and equipment used;
- . Major repair costs for fixed assets that are exceptionally large and occur once.

#### 7. Rules and methods for recording revenues:

Revenue from sales is recognized when the following conditions are simultaneously met:

- . The majority of risks and rewards associated with the ownership of the product or goods have been transferred to the buyer;
- . The company no longer retains the control over the goods as the owner or the right to control the goods;
- . The revenue can be reliably measured;
- . The company has received or will receive economic benefits from the sale transaction;
- . The costs related to the sale transaction can be reliably measured.

#### Financial revenue:

Revenue arising from interest, royalties, dividends, profit sharing, and other financial income is recognized when both of the following conditions are met:

- . There is a reasonable expectation of receiving economic benefits from the transaction;
- . The revenue can be reliably measured.

Unit: Vietnam Dong

#### V. Notes to the Balance sheet

	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>1. Cash</b>		
- Cash	19.259.726.655	2.584.400.686
- Demand deposits	20.792.366.407	28.834.767.496
- Cash equivalents (Deposits with maturity term under 3 months)		
<b>Total</b>	<b>40.052.093.062</b>	<b>31.419.168.182</b>
<b>2. Financial investments</b>	<u><b>31-3-2025</b></u>	<u><b>01-01-2025</b></u>
<i>a) Trading securities</i>		
- Total value of shares;		
- Total value of bonds;		
- Other financial investments;		
- Provision for Decline in Value of Trading Securities		
<i>b) Held to maturity investments</i>		
- Term deposits		
- Bonds		
- Other investments		
<b>Total</b>		
<b>3. Short-term trade receivables</b>	<u><b>31-3-2025</b></u>	<u><b>01-01-2025</b></u>
<i>a) Trade receivables</i>	<i>116.040.539.431</i>	<i>118.236.171.594</i>
- Detail		
<i>b) Trade receivables from relevant entities</i>		
- Detail		
<b>Total</b>	<b>116.040.539.431</b>	<b>118.236.171.594</b>
<b>4. Short-term repayments to suppliers</b>	<u><b>31-3-2025</b></u>	<u><b>01-01-2025</b></u>
<i>a) Repayments to suppliers</i>	<i>89.564.678.572</i>	<i>59.671.572.390</i>
*Detail in PL4		
<i>b) Repayments to relevant entities</i>		
- Detail		
<b>Total</b>	<b>89.564.678.572</b>	<b>59.671.572.390</b>
<b>5. Short-term loan receivables</b>	<u><b>31-3-2025</b></u>	<u><b>01-01-2025</b></u>
- Short-term loan receivables		
<b>Total</b>		



<b>6. Other short-term receivables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Receivables from equitization;		
- Receivables from dividends and profits received;		
- Other receivables.	35.650.000	49.000.000
- Advance	6.482.599.630	6.399.614.849
Advance	68.084.760	68.450.775
- Expenditures on behalf of a third party;	1.609.880	2.204.000
- Receivables from employees;		
- Other	0	
<b>Total</b>	<b>6.587.944.270</b>	<b>6.519.269.624</b>
<b>7. Shortage of assets awaiting resolution</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Cash;</i>		
<i>b) Inventories;</i>		
<i>c) Fixed assets;</i>		
<i>d) Other assets.</i>		
<b>Total</b>		
<b>8. Bad debts</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Total value of receivables, overdue debts or no overdue doubtful debts;		
- Information about fines, deferred interest receivables, etc arising from overdue debts which are not recorded to revenues;		
- Recoverability of overdue debts.	3.671.385.063	3.671.385.063
<b>Total</b>	<b>3.671.385.063</b>	<b>3.671.385.063</b>
<b>9. Inventories</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Goods in transit;		
- Raw materials;	55.935.924.908	54.200.285.889
- Tools and supplies;		
- Work in progress;	17.626.179.930	15.202.316.672
- Finished goods;	57.272.304.060	52.911.355.963
- Goods;	5.193.571.936	5.595.094.560
- Consignments;		
- Goods in bonded warehouse.		
- Real estate		
- Provision for devaluation of stocks		
<b>Total</b>	<b>136.027.980.834</b>	<b>127.909.053.084</b>
- value of unused or degraded inventories which are unsold at the end of fiscal year; reasons and resolutions for unused or degraded inventories;		
- Value of inventories put up as collateral to ensure liabilities at the end of fiscal year;		
<b>10. Short-term prepaid expenses</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Prepaid expenses incurred from fixed asset operating lease;		
- Dispatched tools and supplies;	522.496.858	624.164.224
- Borrowings;		
- Other items		
<b>Total</b>	<b>522.496.858</b>	<b>624.164.224</b>
<b>11. Long-term trade receivables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade receivables</i>		
*Detail in PL4		
<i>b) Trade receivables from relevant entities</i>		
- Detail		
<b>Total</b>		
<b>12. Long-term repayments to suppliers</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Repayments to suppliers</i>		
*Detail in PL4		
<i>b) Repayments to relevant entities</i>		



- Detail

**Total**

	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>13. Other long-term receivables</b>		
- Receivables from equitization;		
- Receivables from dividends and profits received;		
- Other receivables.		
- Advance;		
- Deposits;		
- Expenditures on behalf of a third party;		
- Others		
- Provision for long-term receivables		
<b>Total</b>		
<b>14. Increases or decreases in tangible fixed assets</b>		
*Detail in PL1a		
<b>15. Increases or decreases in finance lease fixed assets</b>	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>16. Increases or decreases in intangible fixed assets</b>		
*Detail in PL1b		
<b>17. Long-term work in progress</b>	<u>31-3-2025</u>	<u>01-01-2025</u>
<i>a) Long-term work in progress</i>		
<i>b) Construction in progress</i>	35.808.425.769	24.432.507.459
- Purchase;		
- Capital investment;	35.808.425.769	24.432.507.459
*Detail in PL1c		
- Repair.		
<b>Total</b>	35.808.425.769	24.432.507.459
<b>18. Long-term financial investments</b>	<u>31-3-2025</u>	<u>01-01-2025</u>
<i>a) Equity investments in other entities</i>		
- Investments in subsidiaries		
- Investments in joint ventures and associates;		
- Investments in other entities;		
- Provision for investments in other entities		
<i>b) Held to maturity investments</i>		
- Term deposits		
- Bonds		
- Loans		
- Other investments		
<b>Total</b>		
<b>19. Long-term prepaid expenses</b>	<u>31-3-2025</u>	<u>01-01-2025</u>
- Prepaid expenses incurred from fixed asset operating lease;		
- Dispatched tools and supplies;	2.350.622.787	2.866.669.162
- Borrowings;		
- Other items		
<b>Total</b>	2.350.622.787	2.866.669.162
<b>20. Deferred tax assets and deferred tax payables</b>	<u>31-3-2025</u>	<u>01-01-2025</u>
<i>a) Deferred tax assets</i>		
- Corporate income tax rates used for determination of value of deferred tax assets	20%	20%
- Deferred tax assets related to unused taxable losses		
- Deferred tax assets related to unused taxable incentives		
- Deferred tax assets related to deductible temporary differences		
- Balance of deferred income tax payables		



**b) Deferred income tax payables**

- Corporate income tax rates used for determination of value of deferred income tax payables
- Deferred income tax payables arising from taxable temporary differences
- Balance of Deferred income tax payables

<b>21. Long-term equipment and spare parts for replacement</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<b>22. Other long-term assets</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<b>23. Short-term trade payables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade payables</i>	<i>59.287.562.007</i>	<i>63.913.046.095</i>
*Detail in PL4		
<i>b) Overdue debts</i>		
*Detail in PL4		
<i>c) Trade payables to relevant entities</i>		
- Detail		
<b>Total</b>	<b>59.287.562.007</b>	<b>63.913.046.095</b>
<b>24. Short-term prepayments from customers</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Prepayments from customers</i>	<i>22.740.801.062</i>	<i>27.011.433.156</i>
- Detail in PL4		
<i>b) Prepayments from relevant entities</i>		
- Detail		
<b>Total</b>	<b>22.740.801.062</b>	<b>27.011.433.156</b>
<b>25. Taxes and other payables to the State</b>		
*Detail in PL5		
<b>26. Short-term expenses</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Expenses for goods without vouchers	387.745.804	11.581.904
- Compensation for board members	706.580.162	356.580.162
- Advertisement expenses		
- Annual leave, holiday break expenses		
- Other accrued expenses	21.176.000	60.000.000
<b>Total</b>	<b>1.115.501.966</b>	<b>428.162.066</b>
<b>27. Short-term unearned revenues</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Unearned revenues;		
- Revenues from traditional client programs;		
- Other unearned revenues.	1.925.701.537	3.201.934.270
<b>Total</b>	<b>1.925.701.537</b>	<b>3.201.934.270</b>
<b>28. Other short-term payables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Surplus of assets awaiting resolution;		
- Funding of trade union;	94.905.540	
- Social insurance; Health insurance; Unemployment insurance;	1.738.850.855	
- Payables on equitization;		
- Deposits;		
- Dividends or profits payables;		
- Other payables.	7.124.751.347	7.182.181.347
<b>Total</b>	<b>8.958.507.742</b>	<b>7.182.181.347</b>
<b>29. Overdue debts</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<b>30. Borrowings and finance lease liabilities</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
*Detail in PL6		
<b>31. Short-term provisions</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>

- Provisions for product warranty;		
- Provision for construction warranty;		
- Provision for enterprise restructuring;		
- Other provision payables (periodical fixed asset repair expenses, environmental restoration expenses, etc)	867.363.665	
<b>Total</b>	<b>867.363.665</b>	
<b>32. Long-term trade payables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade payables</i>		
*Detail in PL4		
<i>b) Overdue debts</i>		
*Detail in PL4		
<i>c) Trade payables to relevant entities</i>		
- Detail		
<b>Total</b>		
<b>24. Long-term prepayments from customers</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Prepayments from customers</i>		
*Detail in PL4		
<i>b) Prepayments from relevant entities</i>		
- Detail		
<b>Total</b>		
<b>34. Long-term provisions</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Provisions for product warranty;		
- Provision for construction warranty;		
- Provision for enterprise restructuring;		
- Other provision payables (periodical fixed asset repair expenses, environmental restoration expenses, etc)		
<b>Total</b>		
<b>35. Long-term unearned revenues</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Detail		
- The possibility of failure to perform a contract		
<b>Total</b>		
<b>28. Other long-term payables</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
- Deposits;		
- Other payables		
<b>Total</b>		
<b>37. Bonds issued</b>	<b><u>31-3-2025</u></b>	<b><u>01-01-2025</u></b>
<i>Common bonds</i>		
<i>a) Bonds issued</i>		
- Bonds issued according to par value;		
- Bonds issued at a discount		
- Bonds issued at premium.		
<b>Total</b>		
<i>b) Detailed description of bonds held by entities (each type of bonds in details)</i>		
<i>Convertible bond</i>		
<i>a) Value of convertible bond</i>		
Equity Structure		
Initial recorded principal debt structure (1)		
Bond issuance costs pending allocation (2)		
Total: Cumulative allocated value of the discount amount		
Opening balance		
Increase in allocation during the year		
Closing balance (2)		



Principal debt structure at year-end = (1) - (2)

*b) Detailed description of bonds held by entities (each type of bonds)*

	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>38. Owner's equity</b>		
<i>a) Comparison table of owner's equity fluctuations</i>		
*Detail in PL2		
<i>b) Contributed capital</i>	<b>279.473.170.000</b>	<b>279.473.170.000</b>
Contributed capital of State		
Contributed capital of Individual	279.473.170.000	279.473.170.000
<i>c) Capital transactions with owners and distribution of dividends or profits</i>	<b>279.473.170.000</b>	<b>279.473.170.000</b>
- Owner's invested equity		
+ Opening equity	279.473.170.000	279.473.170.000
+ Increase in capital during the fiscal year		
+ Decrease in capital during the fiscal year		
+ Closing capital	279.473.170.000	279.473.170.000
- Dividends or distributed profits		
<i>d) Shares</i>		
- Number of shares registered for issuance	27.947.317	27.947.317
- Number of shares sold public market	27.947.317	27.947.317
+ Common shares	27.947.317	27.947.317
+ Preference shares (type of shares classified as owner's equity)		
- Number of shares repurchased (treasury shares)		
+ Common shares		
+ Preference shares (type of shares classified as owner's equity)		
- Number of shares outstanding	27.947.317	27.947.317
+ Common shares	27.947.317	27.947.317
+ Preference shares (type of shares classified as owner's equity)		
* Par value of shares outstanding	10.000	10.000
<i>e) Funds of enterprises:</i>	<b>124.594.214.888</b>	<b>124.594.214.888</b>
- Development investment funds;	124.594.214.888	124.594.214.888
- Enterprise restructuring funds;		
- Other funds.		

	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>39. Exchange differences</b>		
- Exchange differences due to change from financial statement prepared in foreign currency to VND		
- Exchange differences due to other reasons (detailed reasons)		
<b>Total</b>		

	<u>31-3-2025</u>	<u>01-01-2025</u>
<b>40. Funding sources</b>		
- Funding sources granted during the fiscal year		
- Non-business expenses		
- Closing remaining funding sources		

## VII. Notes to the Balance sheet

	<u>Current Year</u>	<u>Previous Year</u>
<b>1. Revenues from sales and services rendered</b>		
<i>a) Revenues from sale</i>	<b>161.570.158.355</b>	<b>146.660.709.799</b>
- Revenues from sale	154.703.340.084	145.069.282.307
- Revenues from services rendered	6.866.818.271	1.591.427.492
- Other revenues		
<i>b) Revenues from relevant entities (every entity in details)</i>		
- Detail		
<b>Total</b>	<b>161.570.158.355</b>	<b>146.660.709.799</b>

	<u>Current Year</u>	<u>Previous Year</u>
<b>2. Revenue deductions</b>		
- Trade discounts;	218.322.409	8.725.591
- Sales rebates;	10.895.238	884.762

- Sales returns;	447.704.549	100.505.113
<b>Total</b>	<b>676.922.196</b>	<b>110.115.466</b>

#### 5. Net revenues from sales and services rendered

	<u>Current Year</u>	<u>Previous Year</u>
- Net revenues from sales	154.026.417.888	144.959.166.841
- Net revenues from services rendered	6.866.818.271	1.591.427.492
- Net revenues from other sources		
<b>Total</b>	<b>160.893.236.159</b>	<b>146.550.594.333</b>

#### 3. Costs of goods sold

	<u>Current Year</u>	<u>Previous Year</u>
- Costs of goods sold;	50.453.961.101	56.709.435.456
- Costs of finished goods sold;	50.453.336.869	43.389.331.535
<b>Total</b>	<b>100.907.297.970</b>	<b>100.098.766.991</b>

#### 4. Financial income

	<u>Current Year</u>	<u>Previous Year</u>
- Interests of deposits or loans	7.198.660	6.915.819
- Interests of investments;		
- Dividends, distributed profits;		
- Interests of exchange differences;	157.663.820	60.957.832
- Interests of sale under deferred payment or payment discounts;		
- Other financial incomes.		
<b>Total</b>	<b>164.862.480</b>	<b>67.873.651</b>

#### 5. Financial expenses

	<u>Current Year</u>	<u>Previous Year</u>
- Interests of loans;	729.036.031	1.038.232.196
- Payment discounts or interests of sale under deferred payment;	316.501.510	308.822.690
- Losses due to disposal of financial investments;		
- Losses of exchange differences;		
- Allowances for decline in value of trading securities and investment impairment;		
- Other financial expenses;	393.509.450	585.786.763
- Decreases in financial expenses.		
<b>Total</b>	<b>1.439.046.991</b>	<b>1.932.841.649</b>

#### 7. Selling expenses and general administration expenses

	<u>Current Year</u>	<u>Previous Year</u>
<b>a) General administration expenses incurred during the fiscal year</b>	<b>21.439.060.473</b>	<b>16.910.555.552</b>
- Administration staff expenses	11.046.759.311	9.029.140.684
- Administrative materials expenses	1.482.831.799	1.166.840.661
- Expenses of tools and supplies	257.343.203	1.368.979.135
- Depreciation expenses of fixed assets	954.878.568	963.542.160
- Taxes, fees and charges	660.607.369	233.388.431
- Provision expenses	1.250.000.000	900.000.000
- Outsourcing services expenses	1.446.885.220	905.506.067
- Other cash expenses	4.339.755.003	2.343.158.414
<b>b) Selling expenses incurred during the fiscal year</b>	<b>20.770.275.738</b>	<b>17.781.438.760</b>
- Selling staff expenses	16.101.945.513	12.450.594.548
- Materials and packing expenses		
- Tools and supplies expenses		
- Depreciation expenses of fixed assets	619.002.309	694.117.974
- Warranty expenses		
- Outsourcing services expenses	1.648.584.328	1.414.007.356
- Other cash expenses	2.400.743.588	3.222.718.882
<b>c) Decreases in selling expenses and general administration expenses</b>		
- Reversion of provisions for good warranty;		
- Reversion of provisions for enterprise reorganizing, other provisions;		



- Other decreases.		
<b>Total</b>	<b>42.209.336.211</b>	<b>34.691.994.312</b>
<b>8. Other income</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Disposal or transfer of fixed asset;	12.785.455	
- Gains from revalue of assets;		
- Collected fines;		
- Deductible taxes;		
- Other items.	116.792.783	260.535.184
<b>Total</b>	<b>129.578.238</b>	<b>260.535.184</b>
<b>9. Other expenses</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Residual value of fixed assets and expenses incurred from transfer or disposal of fixed assets;		
- Losses due to revaluation of assets;		
- Fines;		
- Other items.	1.063.827	8.644.820
<b>Total</b>	<b>1.063.827</b>	<b>8.644.820</b>
<b>10. Corporate income tax expenses of the current year</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
<i>a. Total net profit before tax</i>	<i>16.630.931.878</i>	<i>10.146.755.396</i>
<i>b. Increase (decrease) total profit before corporate income tax</i>	<i>0</i>	<i>0</i>
- Increase		
- Decrease		
<i>c. Total taxable income (a) + (b)</i>	<i>16.630.931.878</i>	<i>10.146.755.396</i>
<i>d. Corporate income tax rate</i>		
<i>e. Adjustment to increase corporate income tax of previous years</i>		
<i>f. Corporate income tax = {(c) * (d)} + (e)</i>	<i>3.326.186.376</i>	<i>2.029.351.079</i>
<b>11. Earnings per share / Diluted EPS</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
Profits after enterprise income tax	13.304.745.502	8.117.404.317
Bonus and welfare fund		
Average shares outstanding		
Earnings per share / Diluted EPS		
<b>12. Operating Costs Classified by Element</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Raw materials cost	70.110.269.768	59.627.979.965
- Labour cost	35.565.429.635	28.844.114.661
- Depreciation expenses of fixed assets	6.967.780.807	6.777.068.686
- Outsourcing services expenses	9.953.443.010	8.980.778.265
- Other cash expenses	10.391.280.962	9.235.085.523
<b>Total</b>	<b>132.988.204.182</b>	<b>113.465.027.100</b>
<b>13. Deferred corporate income tax expenses</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Total deferred corporate income tax expenses.		

## VIII. OTHER INFORMATION

### 1. Potential debts, commitments and other financial information:

No contingent liabilities have arisen from past events that could affect the information presented in the consolidated financial statements, which the Company does not

### 2. Events occurring after the fiscal-year end:

No events have occurred that could affect the information presented in the consolidated financial statements or that could significantly impact the Company's

### 3. Information about relevant entities

a) List of relevant entities

b) Significant transactions with related parties in fiscal year

c) Balances with related parties

Transactions with other related parties:

#### 4. Segment report

#### 5. Financial instrument

##### Financial assets

Cash and cash equivalents

Trade and other receivable

Available For Sale

Short-term investments

Provision

**Total**

##### Equity instruments

Trade and other payables

Accrued expenses

Borrowings

**Total**

##### Liquidity Risk

\*Detail in PL7

#### 6. Financial indicators of business performance

\*Detail in PL3

#### 7. Income of the Board of Directors, CEO, and Supervisory Board

##### 7.1. Income of the Board of Directors, CEO

Nguyễn Trung Việt

Trần Phúc Dương

Nguyễn Thị Tú Anh

Đặng Văn Việt

Phạm Văn Năm

##### 7.2. Income of Supervisory Board

Phạm Thị Thủy

Trần Kim Cương

Nguyễn Thị Hương Lan

#### 8. Comparative Information

#### 9. Information on Going Concern

There are no events that cast significant doubt on the company's ability to continue as a going concern, and the company has no intention nor is it required to cease operations or significantly reduce its scale of operations.

Day 18 month 4 year 2025

**Prepared by**

(Signature and full name)

  
**Trần Quốc Tuấn**

**Chief accountant**

(Signature and full name)

  
**KẾ TOÁN TRƯỞNG**  
**CNKT: CHU VĂN LONG**

**Director**

(Signature, full name and stamp)

  
  
**TỔNG GIÁM ĐỐC**  
**DSCKI: NGUYỄN THỊ TÚ ANH**



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Nguyen Trai Ward, Hai Duong City, Hai Duong, Vietnam

**01a: The increase, decrease of tangible fixed assets**

No	Items	House, architecture	Machines, devices	Means of transmission transportation	Management tools	Total
<b>I</b>	<b>Purchase during the fiscal year</b>					
	<b>Opening balance</b>	<b>172.733.683.489</b>	<b>285.473.219.986</b>	<b>20.264.529.754</b>	<b>2.945.335.539</b>	<b>481.416.768.768</b>
	- Liquidation		(4.008.640.022)		(142.476.190)	(4.151.116.212)
	- Increase from capital construction		432.066.000			432.066.000
	- Increase by purchasing		1.100.000.000			1.100.000.000
	<b>Closing balance</b>	<b>172.733.683.489</b>	<b>282.996.645.964</b>	<b>20.264.529.754</b>	<b>2.802.859.349</b>	<b>478.797.718.556</b>
<b>II</b>	<b>Value of accumulated depreciation</b>					
	<b>Opening balance</b>	<b>57.275.571.913</b>	<b>142.365.068.240</b>	<b>19.176.546.292</b>	<b>2.912.360.534</b>	<b>221.729.546.979</b>
	- Depreciation during the fiscal year	1.206.805.131	5.605.433.029	151.499.892	6.441.819	6.970.179.871
	- Liquidation		(4.008.640.022)		(142.476.190)	(4.151.116.212)
	<b>Closing balance</b>	<b>58.482.377.044</b>	<b>143.961.861.247</b>	<b>19.328.046.184</b>	<b>2.776.326.163</b>	<b>224.548.610.638</b>
<b>III</b>	<b>Remaining value</b>					
	<b>Opening balance</b>	<b>115.458.111.576</b>	<b>143.108.151.746</b>	<b>1.087.983.462</b>	<b>32.975.005</b>	<b>259.687.221.789</b>
	<b>Closing balance</b>	<b>114.251.306.445</b>	<b>139.034.784.717</b>	<b>936.483.570</b>	<b>26.533.186</b>	<b>254.249.107.918</b>

Closing residual value of tangible fixed asset put up as collateral for loans

Fully depreciated fixed assets still being used

116.055.384.033

The commitments to the purchase and sale of tangible fixed assets with great value in the future

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Nguyen Trai Ward, Hai Duong City, Hai Duong, Vietnam

**01b: The increase, decrease of intangible fixed assets**

No	Items	Land use right	Issuing right	Copyright, patent	Other intangible fixed assets	Total
<b>I</b>	<b>Purchase during the fiscal year</b>					
	Opening balance	20.651.287.846			4.906.000.000	25.557.287.846
	Closing balance	20.651.287.846			4.906.000.000	25.557.287.846
	Value of accumulated depreciation					
<b>II</b>	Opening balance	2.399.937.490			4.906.000.000	7.305.937.490
	- Depreciation during the fiscal year					
	Closing balance	2.399.937.490			4.906.000.000	7.305.937.490
	Remaining value					
<b>III</b>	Opening balance	18.251.350.356				18.251.350.356
	Closing balance	18.251.350.356				18.251.350.356
	Closing residual value of tangible fixed asset put up as collateral for loans					

7.305.937.490

Fully depreciated fixed assets still being used

The commitments to the purchase and sale of tangible fixed assets with great value in the future



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**

102 Chi Lang Street, Nguyen Trai Ward, Hai Duong City, Hai Duong, Vietnam

**Appendix 01: Comparison table of owner's equity fluctuations**

Item	Contributed capital	Surplus equity	Other capital	Investment and development fund	Other funds	Undistributed profits after tax and funds	Total
<b>Opening balance at 01/01/2024</b>	<b>203.996.300.000</b>			<b>174.594.214.888</b>		<b>41.544.595.561</b>	<b>420.135.110.449</b>
<b>Increase in capital in fiscal year</b>						<b>8.117.404.317</b>	<b>8.117.404.317</b>
- Profits						8.117.404.317	8.117.404.317
- Increase in capital							
- Spend funds							
<b>Decrease in capital in fiscal year</b>							
- Dividends or distributed profits							
- Set aside funds							
- Other							
<b>Closing balance at 31/03/2024</b>	<b>203.996.300.000</b>			<b>174.594.214.888</b>		<b>49.661.999.878</b>	<b>428.252.514.766</b>
<b>Opening balance at 01/01/2025</b>	<b>279.473.170.000</b>			<b>124.594.214.888</b>		<b>50.191.780.757</b>	<b>454.259.165.645</b>
<b>Increase in capital in fiscal year</b>						<b>13.304.745.502</b>	<b>13.304.745.502</b>
- Profits						13.304.745.502	13.304.745.502
- Increase in capital							
- Spend funds							
<b>Decrease in capital in fiscal year</b>							
- Dividends or distributed profits							
- Set aside funds							
- Other							
<b>Closing balance at 31/03/2025</b>	<b>279.473.170.000</b>			<b>124.594.214.888</b>		<b>63.496.526.259</b>	<b>467.563.911.147</b>

**Appendix 03. Key indicators for assessing the overall financial condition and business performance**

Item	Measurement	Current year at 31/3/2025	Previous year at 31/3/2024
<b>6.1. Capital Structure and Assets Structure</b>			
<i>a. Assets Structure</i>			
- Fixed Assets / Assets	%	44,54	47,22
- Current Assets / Assets	%	55,46	52,78
<i>b. Capital Structure</i>			
- Trade payables / Total capital	%	32,96	29,72
- Owner's equity / Total capital	%	67,04	70,28
<b>6.2. Liquidity</b>			
a. General liquidity	lần	3,03	3,36
b. Short-term liquidity	lần	2,07	1,83
c. Quick liquidity	lần	1,34	1,15
Item	Measurement	First 3 months in 2025	First 3 months in 2024
<b>6.3. Profitability ratio</b>			
<i>a. Profit margin / revenue ratio</i>			
- Profit before tax / Revenue	%	10,29	8,04
- Profit after tax / Revenue	%	8,23	6,42
<i>b. Return on Assets (ROA)</i>			
- Profit before tax / Total assets	%	2,38	2,30
- Profit after tax / Total assets	%	1,91	1,84
<i>c. Net profit after tax / Owner's equity</i>	%	2,85	2,62



**Appendix 01c - Construction in progress**

<b>No.</b>	<b>Construction in progress</b>	<b>Opening balance</b>	<b>Closing balance</b>
19	Chi phí tư vấn GMP EU dây chuyền cephalosporin - Dự án GĐ2	5.921.925.093	6.354.009.976
23	Chi phí tư vấn + thiết kế và ĐTXD Dây chuyền Cepharlosprorin GMPEU - Dự án GĐ2	12.855.006.168	21.793.991.084
32	Chi phí sửa chữa nhà 4a do bão Yagi		1.516.867.000
Chi phí TCDA	Chi phí lãi vay trung hạn của dự án		487.981.511
QSD L09 -54	Giá trị quyền sử dụng đất L09-54 Tại Cần Thơ	2.827.788.099	2.827.788.099
QSD L09-53	Giá trị Quyền sử dụng đất lô L09-53 Tại Cần Thơ	2.827.788.099	2.827.788.099
	<b>Total</b>	<b>24.432.507.459</b>	<b>35.808.425.769</b>

**Appendix 04a - Trade receivables in detail**

No	Customer code	Customer	Previous year		Current Year	
			Value	Provision	Value	Provision
1	1002061	Trung tâm Y tế Huyện Nam Sách	7.382.561.150		6.574.057.948	
2	1001065	Bệnh viện Đa khoa tỉnh Hải Dương	5.911.196.600		5.531.623.216	
3	1002062	Trung tâm Y tế huyện Tứ Kỳ	4.355.255.977		4.295.010.677	
4	1002056	Trung tâm y tế huyện Bình Giang	2.482.472.650		3.785.136.731	
5	PKD-1xx-0375	KARUNA PHARMA CO,LTD	6.520.562.745		3.246.219.075	
6	1036207	Công ty cổ phần dược phẩm trung ương CPC1-Chi nhánh Nghệ An	2.726.205.469		2.839.796.974	
7	1002063	Trung tâm Y tế huyện Thanh Hà	3.272.031.580		2.626.369.980	
8	1002059	Trung tâm y tế thị xã Kinh Môn	2.321.903.139		2.025.551.378	
9	1000681	Công ty TNHH Golden Health USA (KH)	2.259.924.512		2.011.570.134	
10	1002046	Trung tâm Y tế huyện Cẩm Giàng	2.414.932.106		1.912.623.960	
11	Others	Others	78.589.125.666		81.192.579.358	
<b>Total</b>			<b>118.236.171.594</b>		<b>116.040.539.431</b>	

**Appendix 04c - Customers pay in advanced**

No	Customer code	Customer	Previous year		Current Year	
			Value	Provision	Value	Provision
1	1000309	Công ty Cổ phần Dược phẩm Hoàng Giang	3.737.005.260		3.729.928.239	
2	1000400	Công ty TNHH Thương mại và Công nghệ Hà Minh	3.682.738.650		2.214.177.730	
3	3000136	Công ty TNHH Thương mại Dược phẩm IPP	1.462.230.000		1.559.430.000	
4	3000773	CÔNG TY TNHH SOLPHARMA	886.690.000		1.115.240.000	
5	3000422	Công ty Cổ phần World Roche ( Bayer World )...	492.650.000		871.746.000	
6	3000730	CÔNG TY CỔ PHẦN VIỆT NAM PHARUSA			817.484.020	
7	3000422	Công ty Cổ phần World Roche ( Bayer World )...	618.405.600		708.475.815	
8	3000254	Công ty TNHH Thương mại và dịch vụ 2B	495.521.250		586.530.000	
9	3000538	Nguyễn Văn Thành (Quảng Bình)	500.000.000		500.000.000	
10	3000770	CÔNG TY TNHH DƯỢC VÀ VẬT TƯ Y TẾ DG	495.000.000		495.000.000	
11	3000149	Công ty Cổ phần Dược VP-PHARM	478.725.045		478.725.045	
12	3000602	Công ty Cổ phần Sanoji World ( Bayer World)...	360.003.234		465.012.876	
13	3000419	Công ty cổ phần Hà Nội SKV	460.792.500		460.792.500	
14	3000731	CÔNG TY CỔ PHẦN DƯỢC ĐÔNG BẮC MEDICINE	100.000.000		443.507.500	
15	3000652	Công ty TNHH Đắc Hà	379.893.750		379.893.750	
16	Others	Others	12.861.777.867		7.914.857.587	
<b>Total</b>			<b>27.011.433.156</b>		<b>22.740.801.062</b>	



**Appendix 04b - Trade payables in detail**

No	Customer code	Customer	Previous year		Current year	
			Value	Provision	Value	Provision
1	1000564	Công ty Cổ phần Dược phẩm Thuận An Phát	3.882.712.100	3.882.712.100	3.290.759.449	3.290.759.449
2	1000766	Công ty Cổ phần hóa dược quốc tế Hà Nội	3.087.099.550	3.087.099.550	3.115.148.850	3.115.148.850
3	1000483	Công ty Trách nhiệm hữu hạn Thương mại Dược phẩm Vạn Xuân	3.011.560.416	3.011.560.416	3.011.560.416	3.011.560.416
4	1000389	Công Ty TNHH Sản xuất Bao Bì Và Thương Mại Đức Thành	1.715.471.805	1.715.471.805	2.865.061.487	2.865.061.487
5	1000477	Công ty cổ phần Thủy Tinh Hưng Phú	1.610.031.600	1.610.031.600	2.846.411.280	2.846.411.280
6	1000307	Công ty Cổ phần Dược phẩm và Thương mại Đông Dương ...	2.634.839.674	2.634.839.674	2.666.436.834	2.666.436.834
7	1000395	Công ty TNHH Thương Mại Và Sản Xuất Đông Âu	2.685.110.449	2.685.110.449	2.548.133.976	2.548.133.976
8	3000339	Công ty Cổ phần CGP Việt Nam	0	0	2.531.112.192	2.531.112.192
9	1036937	Công ty cổ phần trang thiết bị Y tế Dược phẩm Hoàng Ngọc	3.552.853.700	3.552.853.700	2.282.511.420	2.282.511.420
10	1000906	Chi nhánh Công ty Cổ phần Dược DANAPHA tại TP Hà Nội	552.783.532	552.783.532	1.475.622.213	1.475.622.213
11	Others	Other payables	41.180.583.269	41.180.583.269	32.654.803.890	32.654.803.890
Total			63.913.046.095	63.913.046.095	59.287.562.007	59.287.562.007

**Appendix 04b - Pay for vendors in advanced**

No	Customer No	Customer	Previous year		This year	
			Value	Provision	Value	Provision
1	5006608	Công ty TNHH cơ nhiệt điện lạnh Bách Khoa	10.398.888.889	10.398.888.889	25.254.444.445	25.254.444.445
2	5006403	IMA Pacific Company Limited	21.242.959.500	21.242.959.500	21.242.959.500	21.242.959.500
3	5006432	ALEXANDERWERK GMBH	4.082.243.787	4.082.243.787	12.376.437.417	12.376.437.417
4	5006453	GEA Process Engineering (India) Pvt Ltd (Unit II, 100% EOU)	5.925.729.471	5.925.729.471	5.925.729.471	5.925.729.471
5	5006569	Công ty TNHH Atlas Copco Việt Nam	1.046.196.000	1.046.196.000	4.707.882.000	4.707.882.000
6	5006567	ZHEJIANG CANAAN TECHNOLOGYLIMITED	1.471.324.350	1.471.324.350	4.478.101.689	4.478.101.689
7	5006565	Truking Watertown Pharmaceutical Equipment Co., Ltd	4.155.102.900	4.155.102.900	4.397.827.900	4.397.827.900
8	5006541	Công ty cổ phần xây dựng Alphaco Hà Nội	5.855.966.623	5.855.966.623	2.109.253.889	2.109.253.889
9	5006640	ZHEJIANG TAILIN SCITECH CO., LTD			1.233.782.550	1.233.782.550
10	5006600	BROTHERS PHARMAMACH (INDIA) PVT. LTD	1.084.510.800	1.084.510.800	1.084.510.800	1.084.510.800
11	Others	Others	4.408.650.070	4.408.650.070	6.753.748.911	6.753.748.911
Total			59.671.572.390	59.671.572.390	89.564.678.572	89.564.678.572

**Appendix 05-Taxes and other payables to the State**

Item	01/01/ 2025		Payable during the fiscal year	Paid amount during the fiscal year	31/3/2025	
	Receivables	Payables			Receivables	Payables
- Value added tax			12.266.690.257	12.266.690.257		
- Special consumption tax						
- Import and export tax			8.388.657	8.388.657		
- Corporate income tax		6.302.229.077	3.326.186.376	6.302.229.077		3.326.186.376
- Personal income tax		849.808.878	322.830.712	1.575.706.181	403.066.591	
- Resource tax						
- Real estate tax, land rent			500.000.000			500.000.000
- Other taxes			132.556.983	132.556.983		
- Fees, charges and other payables						
<b>Total</b>		<b>7.152.037.955</b>	<b>16.556.652.985</b>	<b>20.285.571.155</b>	<b>403.066.591</b>	<b>3.826.186.376</b>

(\*) Amount of corporate income tax provisionally paid

- Amount of corporate income tax provisionally paid 6.302.229.077

- Corporate income tax exemption (support female employees)

- Adjusted corporate income tax at the branch

**Total 6.302.229.077**

Payable amount of corporate income tax settled in the period

- Payable amount of corporate income tax settled in the period 3.326.186.376

- Adjusted corporate income tax at the branch

**Total 3.326.186.376**



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Nguyen Trai Ward, Hai Duong City, Hai Duong, Vietnam

**Appendix 06- Borrowings and finance lease liabilities**

Item	Opening balance	Increase	Decrease	Closing balance
<b>a) Short-term borrowings and finance lease liabilities</b>				
- Short-term borrowings	65.925.328.072	31.773.011.393	34.361.531.923	63.336.807.542
- Overdue borrowings				
- Short-term finance lease liabilities				
<b>b) Long-term borrowings and finance lease liabilities</b>				
- Borrowings	6.002.713.990	37.360.855.450		43.363.569.440
- Long-term finance lease liabilities				

**Appendix 07- Payment Risk**

Liquidity risk is the risk that HDPHARMA will encounter difficulty in meeting financial obligations due to a shortage of funds. HDPHARMA's liquidity risk primarily arises from mismatches in the maturities of financial assets and financial liabilities.

HDPHARMA monitors liquidity risk by maintaining a level of cash and cash equivalents deemed adequate by the Board of Directors to finance HDPHARMA's business operations and to mitigate the effects of fluctuations in cash flows.

The maturity information of HDPHARMA's financial liabilities based on undiscounted contractual payments is as follows:

Item	Under 01 year	From 01 to 05 years	Total
<b>Closing balance</b>			
Borrowings	63.336.807.542	43.363.569.440	106.700.376.982
Trade payables	59.287.562.007		59.287.562.007
Accrued expenses	1.115.501.966		1.115.501.966
Other payables	8.958.507.742		8.958.507.742
<b>Opening balance</b>			
Borrowings	65.925.328.072	6.002.713.990	71.928.042.062
Trade payables	63.913.046.095		63.913.046.095
Accrued expenses	428.162.066		428.162.066
Other payables	7.182.181.347		7.182.181.347

HDPHARMA considers the concentration of risk regarding debt repayment to be low. HDPHARMA is capable of meeting its maturing debt obligations through cash flows from operating activities and proceeds from maturing financial assets.

